Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
February 2021
in “Cureus”
TLDR Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
Three years ago, a randomized, double-blind, placebo-controlled trial involving 87 male participants with mild to moderate COVID-19 symptoms found that early antiandrogen therapy with Dutasteride significantly reduced viral shedding, inflammatory responses, and time-to-remission. The Dutasteride group experienced a 46.6% reduction in recovery time for fatigue, a 49.6% reduction for loss of taste or smell, and a 43.2% reduction in overall symptom duration compared to the placebo group. Additionally, 64.7% of the Dutasteride group had undetectable SARS-CoV-2 virus or viral fragments by Day 7, compared to 11.8% in the placebo group. Biochemical parameters related to inflammatory responses were also significantly reduced in the Dutasteride group. No serious adverse effects were reported. The study concluded that Dutasteride could potentially increase the speed of COVID-19 remission and reduce the period of viral transmission. However, the efficacy and safety of dutasteride for women remained uncertain.
View this study on cureus.com →
Cited in this study
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
AGA linked to worse COVID-19 outcomes in men.
research Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
Women with high androgen levels may have more severe COVID-19 symptoms.
research Androgen receptor genetic variant predicts COVID‐19 disease severity: a prospective longitudinal study of hospitalized COVID‐19 male patients
A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
research Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.
research Repurposing existing drugs for COVID-19: an endocrinology perspective
Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
research Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
research Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Spironolactone might help protect against severe lung problems in COVID-19 patients.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
Related
research Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
research Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
research Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.
research Dutasteride improves male pattern hair loss in a randomized study in identical twins
Dutasteride helps slow hair loss and boosts hair growth.